From research to clinical excellence
MagIA diagnostics was founded in 2017 and is based in Grenoble (France). We have developed a highly innovative and generic technology allowing for easy transfer of any immunoassay onto our portable system. We develop a unique panel of infectious diseases assay chips, starting with a Hepatitis B and a combined HIV / Hepatitis screening panel to enhance access to care.
MagIA diagnostics technology results from 15 years of collaboration between several research institutes. The company’s multi-patented core innovation was co-developed during their PhDs by our CTO Guillaume Blaire (2013), and Sarah Delshadi (2017) who now leads the biochemical & regulatory groups. The consortium called upon Paul Kauffmann, now CEO, who has worked from almost 10 years in the biomedical field in the US and France. Mario Fratzl soon joined the team (PhD 2018) on mechanical and fluidics R&D. The highly interdisciplinary team was completed by the arrival of our CFO Cédric Bruix in 2017, bringing us 20+ years’ experience in the investment fund industry.
Supported during 2 years by the incubation program in SATT Linksium and by G2Elab, MagIA was award-winner at the Innovation National Contest CREADEV in 2017, leading to the incorporation of the Company in July 2017.
Paul is the project leader of MagIA Diagnostics. After a PhD in magnetism applied to biomanipulation in Grenoble, Paul evolved internationally in the US and in France in two start-up companies mainly focused on cell manipulation and innovative throughput screening solutions. In December 2014, he returned to Grenoble to join our group and launch the start-up.
Guillaume co-invented the MagIA diagnostics technology during his PhD in Grenoble. After majoring in physics, Guillaume developed a profound interest in biophysics. An interdisciplinary project between the founders’ labs offered him the possibility to explore the potential of micromagnetism in immunological research.
After graduating from ESSEC Business School (Paris), Cédric worked at Banque Paribas in France and in New York in structured finance transactions. In 1999, he joined the European private equity investor, Argos Soditic, where he spent 17 years (inc.10 years as partner) leading investments in France and in Switzerland. Cédric joined MagIA Diagnostics in 2017, in charge of Finance & Administration.
Head of Biological Development
Sarah is the biologist of the team, trained in in vitro diagnostics. In 2013, she developed a biomolecular test for infectious diseases at the Institut Pasteur (Madagascar). During her PhD (IAB and G2ELab), she developed the MagIA protocol. Since 2017, she overviews the transfer of clinical assays and regulatory affairs at MagIA diagnostics.
Head of Mechanical Development
Mario joined the MagIA Diagnostics team in spring 2015 as a masters student in mechatronics engineering. He possesses strong skills in microfluidics, mechanical modeling and design. He is currently preparing his PhD, during which he is developing innovative, micromagnetic structures for MagIA.
Lydia joined MagIA diagnostics as an intern, during which she initiated the implementation of a quality management system. In 2018, she graduated (Master-degree in “in-vitro diagnostics and biomarkers”) at the University of Grenoble-Alpes. Now, she leads the quality management and regulations activities.
Damien started at MagIA with a six-month internship where he learned about the technology and helped develop the system. After graduating from Télécom Physique Strasbourg, he joined the team as an R&D engineer, ready to put to use his skills in electronics and computer programming.
They trust and finance us.
Supports nanoscience and healthcare projects shared by regional labs and R&D partners
BPI France - iLab
Supports our R&D efforts through an iLab grant
Supports the development of a Point-of-Care system for Cystatine detection in saliva